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LIFE AFTER MENOPAUSE: HORMONE REPLACEMENT OR NOT
By Terry Brenner
University Relations

Time was when women had little cause to think much about life after menopause. They
typically died before they reached that age. In fact, as recently as the turn of this century, their
average life expectancy was 47-49 years.
Today women live, on average, well into their 70s or beyond. A third of their lives still
awaits them after menopause, giving them the opportunity to experience hot flashes, urinary
incontinence, vaginitis and menopausal syndrome —mood swings and depression often
complicated by “empty-nest syndrome.”
For most women, those problems associated with estrogen deprivation pass without
severely disrupting their lives, with the exception of hot flashes at night.
“But estrogen deprivation can lead to more serious problems such as osteoporosis and
cardiovascular disease,” says Gayle Cochran, professor and chair of pharmacy practice at The
University of Montana. “Estrogen deprivation also may prove to be associated with cognitive
decline, colon cancer and tooth loss.”
Efforts by doctors and researchers to help women protect their post-menopausal health
have brought women face to face with a confusing array of drugs and decisions about what’s
best for their bodies once the protective estrogen hormone supply has essentially dried up. This
is where hormone replacement therapy comes in.
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Note that this isn’t called estrogen replacement therapy. The ovaries put out another
female hormone, progestin, which is an important part of HRT for women who still have a
uterus.
“Without progestin to balance the estrogen, the uterine lining cells will overproliferate,
and some of those cells can become cancerous,” Cochran says. Progestin’s inclusion in HRT
prevents the overproduction of cells that can lead to uterine malignancy.
So what will be the HRT of choice? Here are some of the options:
■ Eight oral estrogens, including Premarin, Cenestin, Ortho-Est and Estratab.
■ Oral progestins Provera and Cycrin, one of which would probably be used with any
of the estrogens.
■ Two combination products, Prempro and Premphase.
To those choices add this one -- whether to use hormone replacements daily or
sequentially.
Possible nuisance side effects are further considerations - nausea, vomiting, abdominal
cramps, bloating, breast tenderness and enlargement, weight change, vaginal bleeding and
changes in libido, either up or down.
“Most of these will respond to a change in HRT dosage within several months,
however,” Cochran says. And the side effects pale when weighed against the benefits of HRT,
she says. The data supporting therapy are just too good to ignore: 48 percent reduction in
cardiovascular disease, 49 percent reduction in osteoporosis and a possible 30-40 percent
reduction in dementia. HRT does not increase the risk of ovarian cancer, and the eightfold
increase in incidence of uterine cancer can be eliminated with the combined use of estrogen and
progestin. That’s good news.
“The bad news is, breast cancer risk increases slightly over tim e,” Cochran says. And
HRT poses some other major health risks -- a threefold increase in risk of blood clots and a
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two- to fourfold increase in risk of gall bladder disease.
LDL, the lipoprotein in the blood that dumps its cholesterol load in the artery walls,
goes down; and HDL, the lipoprotein that hauls cholesterol out of the arteries into the liver for
disposal, goes up. That’s good. Triglycerides, a type of fat in the blood, also go up, and that’s
not good. But these metabolic side effects can be reduced with transdermal estrogen, also
called the estrogen patch, Cochran says.
With so many issues to consider, women understandably have difficulty choosing
whether to go into HRT. Cochran, however, believes all women need it, in some form or
another.
“Those who won’t consider the traditional choices should look into phytoestrogens,”
she says. These are plant compounds with estrogenic and anti-estrogenic properties, and more
than 300 plant species contain them. Commonly labeled flavones, flavonols, flavanones,
isoflavones and lignans, they are found in red and yellow fruits and vegetables, citrus fruits,
legumes and cereals. Red clover and soy products - soy milk and tofu, especially —are good
sources, too, Cochran says.
The pros and cons of hormone replacement therapy are different for every woman, but
Cochran encourages women not to be put off by the complicated picture HRT presents. It can
be clarified with the help of a physician or medical expert knowledgeable about the patient’s
overall health history, and careful selection of the right product can lead to good outcomes.
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